In a significant turn of events, Cigna Group has ceased its efforts to merge with fellow health-insurance provider Humana. Initially poised to form a colossal entity valued at approximately $140 billion, the deal’s dissolution arose primarily due to disagreements over financial terms. Despite prior discussions hinting at a possible closure by year’s end, the proposed cash-and-stock transaction faced skepticism, particularly concerning the use of Cigna’s stock as a part

In a move that could reshape the health insurance landscape, industry giants Cigna and Humana are reportedly in advanced discussions for a monumental merger. This deal, valued at an estimated $140 billion, is poised to create a new leader in the health insurance sector. We delve into the implications of this potential merger and how it could redefine competitive dynamics in the industry. The Merger: A Strategic Game-Changer Cigna

In an anticipated leadership shake-up, Bruce Broussard, Humana‘s CEO with over a decade at the helm, will relinquish his role as the head of the insurance giant known for its brands like CenterWell in home health, pharmacy, and primary care domains. Taking his place, starting January 8, 2024, will be Jim Rechtin, who currently leads Envision Healthcare. This transition will see Rechtin collaborating closely with Broussard until the second

The U.S. District Court for the District of Columbia in January 2017 found that Aetna’s proposed merger with Humana fell afoul of antitrust laws and ordered it to stop. According to Judge John Bates, the efficiencies generated by the merger will not be sufficient to mitigate the anti-competitive effects for consumers, specifically in respect of individual Medicare Advantage plans and of individual commercial insurance on the public exchanges in

U.S. health insurance providers Aetna and Humana in December 2016 announced they had come to an agreement to extend the deadline for their proposed merger from December 31, 2016 to February 15, 2017, as U.S. federal courts are poised to decide whether to allow the merger to proceed. The decision is expected by mid-January. The deal was first announced in August 2015.

Shareholders of Aetna and Humana in October 2015 voted separately and approved overwhelmingly the health insurers’ proposed $37 billion merger. Aetna shareholders approved the issuance of up to 127 million common shares to Humana stockholders, who agreed to the terms of the July 2015 merger agreement with Aetna as finalized in July. The deal is expected to close in the second half of 2016 after the approval of state

Aetna will acquire Humana for cash and stock valued at $37 billion. The acquisition will push Aetna’s Medicare Advantage membership to  4.4 million and make it possible for the two companies to share knowledge and innovations in order to create better healthcare products, the company said. The deal is subject to regulatory and other approvals; it is expected to be completed in late 2015.